2m 2m 2m 2m 2m 2m 2m
AMYLYX PHARM (AMLX)
NASDAQ
$16.76+$0.47 (+2.92%)
Price as of Jun 23, 2026 11:43 AM EDT- $1.8BMarket Cap
- 224.30%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
AMYLYX PHARM (AMLX)
$16.76+$0.47 (+2.92%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 -100.00% | 87.4M -77.06% | 380.8M +1,612.94% | 22.2M N/A | |
Cost of Revenue | 0 -100.00% | 6.0M -76.60% | 25.4M +750.02% | 3.0M N/A | |
Gross Profit | 0 -100.00% | 81.4M -77.09% | 355.3M +1,747.20% | 19.2M N/A | |
Sales and Marketing Expense | 62.9M -45.00% | 114.3M -39.30% | 188.4M +48.16% | 127.1M N/A | |
Research and Development Expense | -90.4M -13.14% | -104.1M -18.80% | -128.2M +37.17% | -93.5M N/A | |
Depreciation and Amortization Expense | 525,000 -41.92% | 904,000 -16.91% | 1.1M +123.41% | 487,000 N/A | |
Total Operating Expenses | 153.3M -61.88% | 402.1M +17.58% | 342.0M +52.96% | 223.6M N/A | |
Operating Profit | -153.3M -51.29% | -314.7M -911.12% | 38.8M +119.27% | -201.3M N/A | |
Interest Income | 9.3M -32.64% | 13.8M -14.52% | 16.2M +276.49% | 4.3M N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 9.3M -32.64% | 13.8M -14.52% | 16.2M +276.49% | 4.3M N/A | |
Total Nonoperating Income and Expense | 8.6M -31.70% | 12.6M -18.72% | 15.5M +314.30% | 3.7M N/A | |
Income before Taxes | -144.7M -52.11% | -302.1M -656.45% | 54.3M +127.48% | -197.6M N/A | |
Income Taxes | 46,000 +111.70% | -393,000 -107.82% | 5.0M +549.35% | 774,000 N/A | |
Extraordinary Items | N/A N/A | 958,000 N/A | N/A N/A | 0 N/A | |
Net Income | -144.7M -52.03% | -301.7M -712.42% | 49.3M +124.84% | -198.4M N/A | |
Net Income from Continuing Operations Applicable to Common | -144.7M -52.11% | -302.1M -656.45% | 54.3M +127.48% | -197.6M N/A | |
Basic EPS and Net Income | -1.53 -65.46% | -4.43 -706.85% | 0.73 +121.53% | -3.39 N/A | |
Diluted EPS and Net Income | -1.53 -65.46% | -4.43 -732.86% | 0.70 +120.65% | -3.39 N/A | |
Basic Weighted Average Shares | 94.6M +38.78% | 68.1M +1.35% | 67.2M +14.94% | 58.5M N/A | |
Diluted Weighted Average Shares | 94.6M +38.78% | 68.1M -2.64% | 70.0M +19.65% | 58.5M N/A | |
Balance Sheet | |||||
Cash and Cash Equivalents | 226.7M +192.86% | 77.4M -54.53% | 170.2M +172.21% | 62.5M N/A | |
Short-Term Investments | 90.3M -8.86% | 99.1M -50.73% | 201.2M -29.27% | 284.4M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 317.0M +79.59% | 176.5M -52.47% | 371.4M +7.04% | 346.9M N/A | |
Total Current Assets | 323.7M +70.86% | 189.4M -59.23% | 464.7M +21.60% | 382.1M N/A | |
Accumulated Depreciation | 1.6M +14.35% | 1.4M -16.52% | 1.6M +201.48% | 540,000 N/A | |
Property and Plant and Equipment and Net | 310,000 -67.74% | 961,000 -64.22% | 2.7M +2.87% | 2.6M N/A | |
Total Long-Term Assets | 310,000 +1,191.67% | 24,000 -96.58% | 701,000 +50.43% | 466,000 N/A | |
Total Assets | 332.6M +71.79% | 193.6M -62.58% | 517.5M +32.19% | 391.5M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 22.7M -20.13% | 28.4M -65.38% | 82.0M +76.02% | 46.6M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | 42.0M +51.62% | 27.7M N/A | |
Total Long-Term Liabilities | 4.7M +914.69% | 463,000 -76.62% | 2.0M -53.65% | 4.3M N/A | |
Total Liabilities | 27.4M -5.14% | 28.9M -65.64% | 84.0M +65.25% | 50.8M N/A | |
Retained Earnings | -751.4M +23.86% | -606.7M +98.95% | -304.9M -13.91% | -354.2M N/A | |
Total Stockholders Equity | 305.3M +85.27% | 164.8M -61.99% | 433.4M +27.25% | 340.6M N/A | |
Total Shares Outstanding | 109.9M +60.11% | 68.6M +1.36% | 67.7M +1.80% | 66.5M N/A | |
Cash Flow | |||||
Cash from Operating Activities | -123.3M -26.43% | -167.6M -1,506.55% | 11.9M +106.63% | -179.9M N/A | |
Capital Expenditures | 138,000 -12.10% | 157,000 -87.35% | 1.2M -50.87% | 2.5M N/A | |
Cash from Investing Activities | 14.0M -81.44% | 75.7M -17.81% | 92.1M +138.52% | -239.0M N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 257.0M +73,758.91% | 348,000 -90.18% | 3.5M -99.18% | 431.8M N/A | |
Financials Ratio | |||||
Gross Margin | N/A N/A | 93.19% -0.14% | 93.32% N/A | N/A N/A | |
Operating Margin | N/A N/A | -360.22% -3,635.07% | 10.19% N/A | N/A N/A | |
Return on Assets | -55.00% -35.19% | -84.87% -882.79% | 10.84% N/A | N/A N/A | |
Return on Equity | -61.59% -38.95% | -100.88% -892.44% | 12.73% N/A | N/A N/A | |
Revenue Growth | -100.00% +29.78% | -77.06% -104.78% | 1,612.94% N/A | N/A N/A | |
Current Ratio | 14.27 +113.93% | 6.67 +17.74% | 5.66 N/A | N/A N/A | |
Cash Ratio | 9.99 +266.67% | 2.72 +31.33% | 2.07 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow